

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6946720

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	VERNALIS (CAMBRIDGE) LIMITED	10/11/2012
RECEIVING PARTY DATA		
Name:	VERNALIS (R&D) LIMITED	
Street Address:	GRANTA PARK	
City:	GREAT ABINGTON, CAMBRIDGE	
State/Country:	UNITED KINGDOM	
Postal Code:	CB21 6GB	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	16528278
CORRESPONDENCE DATA		
Fax Number:	(202)824-3001	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	(202) 824-3000	
Email:	bwptopat@bannerwitcoff.com, mreed@bannerwitcoff.com	
Correspondent Name:	BANNER & WITCOFF, LTD.	
Address Line 1:	1100 13TH ST. NW	
Address Line 2:	STE 1200	
Address Line 4:	WASHINGTON, D.C. 20005	
ATTORNEY DOCKET NUMBER:	007962.00039	
NAME OF SUBMITTER:	SUSAN A. WOLFFE	
SIGNATURE:	/Susan A. Wolffe/	
DATE SIGNED:	09/30/2021	
Total Attachments: 10		
source=Assignment Vernalis Cambridge to Vernalis R&D#page1.tif		
source=Assignment Vernalis Cambridge to Vernalis R&D#page2.tif		
source=Assignment Vernalis Cambridge to Vernalis R&D#page3.tif		
source=Assignment Vernalis Cambridge to Vernalis R&D#page4.tif		
source=Assignment Vernalis Cambridge to Vernalis R&D#page5.tif		

source=Assignment Vernalis Cambridge to Vernalis R&D#page6.tif
source=Assignment Vernalis Cambridge to Vernalis R&D#page7.tif
source=Assignment Vernalis Cambridge to Vernalis R&D#page8.tif
source=Assignment Vernalis Cambridge to Vernalis R&D#page9.tif
source=Assignment Vernalis Cambridge to Vernalis R&D#page10.tif

VERNALIS (CAMBRIDGE) LIMITED

AND

VERNALIS (R&D) LIMITED

PATENT DEED OF ASSIGNMENT

THIS DEED OF ASSIGNMENT is made on 11 October 2012 (the “Effective Date”)

BETWEEN:

- (1) **VERNALIS (CAMBRIDGE) LIMITED**, a company incorporated in England and Wales (registered no. 03219804), whose registered office is at 100 Berkshire Place, Wharfedale Road, Winnersh, Berkshire RG41 5RD (the “Assignor”); and
- (2) **VERNALIS (R&D) LIMITED**, a company incorporated in England and Wales (registered no. 01985479), whose registered office is at 100 Berkshire Place, Wharfedale Road, Winnersh, Berkshire RG41 5RD (the “Assignee”).

THE PARTIES AGREE as follows:

1. DEFINITIONS

In this Deed of Assignment:

“Applications” means the patent applications listed in part B of the schedule to this Assignment;

“Patents” means together the applications and the registered patents listed in the Schedule; and

“Registered Patents” means the registered patents listed in part A of the schedule to this Assignment.

2. ASSIGNMENT

The Assignor hereby assigns and transfers to the Assignee absolutely with full title guarantee:

2.1.1 all of its right, title and interest in and to the Patents and all legal rights and immunities (howsoever derived) attaching thereto and including (without limitation):

- (a) the right to sue for and to recover damages and other remedies in respect of any infringement of the Patents or other acts carried out by another person within the scope of the claims of any published specification of any of the Patents which may have occurred before the Effective Date; and
- (b) the right to apply for, prosecute and obtain patents or similar rights or protection in respect of any of the inventions the subject matter of the Patents in any country of the world (including the right to claim priority from the Patents).

3. FURTHER ASSURANCE

The Assignor shall on request by the Assignee and at the Assignees expense do and execute or arrange for the doing and executing of, each necessary act, document and thing reasonably within its power to implement this Deed of Assignment.

4. ASSISTANCE WITH APPLICATIONS

The Assignor shall on request by the Assignee and at the Assignee's expense give such assistance as the Assignee may reasonably request with the prosecution to grant of the Applications.

5. ASSISTANCE WITH PROCEEDINGS

If in any proceedings a claim is made, at any time following the Effective Date, impugning the validity of a Registered Patent or a patent granted pursuant to an Application, the Assignor shall give all reasonable assistance to the Assignee in relation to those proceedings (including by participation in the proceedings) subject to the payment by the Assignee of all the Assignor's reasonable costs in relation to those proceedings.

6. GOVERNING LAW

This Deed of Assignment is governed by English law.

SCHEDULE

Part A - Registered Patents

Owners	Country	Application Date	Application No.	Publication No.	Registration Date	Registration No.	Case Status
Vernalis (Cambridge) Ltd.;The Institute of Cancer Research;Cancer Research Technology Limited	China	26-Aug-2004	200480024701.3	WO 2005/021552	28-Jan-2009	ZL 200480024701.3	Granted/Registered
Vernalis (Cambridge) Ltd.;The Institute of Cancer Research;Cancer Research Technology Limited	Eurasian Patent Organization	26-Aug-2004	200600509	WO 2005/021552	28-Apr-2008	009920	Granted/Registered
Vernalis (Cambridge) Ltd.;The Institute of Cancer Research;Cancer Research Technology Limited	Hong Kong	26-Aug-2004	07102556.5	WO 2005/021552	06-Nov-2009	HK1095591	Granted/Registered
Vernalis (Cambridge) Ltd.;The Institute of Cancer Research;Cancer Research Technology Limited	Japan	26-Aug-2004	2006-524418	WO 2005/021552	15-Jul-2011	4783731	Granted/Registered
Vernalis (Cambridge) Ltd.;The Institute of Cancer Research;Cancer Research Technology Limited	Republic of Korea	26-Aug-2004	10-2006-7004012	WO 2005/021552	17-Apr-2012	1139314	Granted/Registered
Vernalis (Cambridge) Ltd.;The Institute of Cancer Research;Cancer Research Technology Limited	Mexico	26-Aug-2004	PA/ai/2006/002118	WO 2005/021552	12-Mar-2010	274447	Granted/Registered
Vernalis (Cambridge) Ltd.;The Institute of Cancer Research;Cancer Research Technology Limited	New Zealand	26-Aug-2004	546044	WO 2005/021552	07-Jan-2010	546044	Granted/Registered
Vernalis (Cambridge) Ltd.;The Institute of Cancer Research;Cancer Research Technology Limited	United States of America	26-Aug-2004	10/569287	WO 2005/021552	26-Oct-2010	7820658	Granted/Registered
Vernalis (Cambridge) Ltd.;The Institute of Cancer Research;Cancer Research Technology Limited	South Africa	26-Aug-2004	2006/01715	WO 2005/021552	30-May-2008	2006/01715	Granted/Registered
Vernalis (Cambridge) Ltd.;The Institute of Cancer Research;Cancer Research Technology Limited	Armenia	09-Feb-2004	200501272		28-Apr-2008	009919	Granted/Registered
Vernalis (Cambridge) Ltd.;The Institute of Cancer Research;Cancer Research Technology Limited	Australia	09-Feb-2004	2004210779	WO 2004/072051	23-Sep-2010	2004210779	Granted/Registered

Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	Azerbaijan	09-Feb-2004	200501272			28-Apr-2008	009919	Granted/Registered
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	Belarus	09-Feb-2004	200501272			28-Apr-2008	009919	Granted/Registered
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	Canada	09-Feb-2004	2515726		WO 2004/072051	10-Jul-2012	2515726	Granted/Registered
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	China	09-Feb-2004	200480009338.2		WO 2004/072051	28-Apr-2010	ZL 200480009339.2	Granted/Registered
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	Eurasian Patent Organization	09-Feb-2004	200501272		WO 2004/072051	28-Apr-2008	009919	Granted/Registered
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	Germany	09-Feb-2004	04709273.9		1611112	22-Aug-2012	1611112	Granted/Registered
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	Ireland	09-Feb-2004	04709273.9		1611112	22-Aug-2012	1611112	Granted/Registered
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	Hong Kong	09-Feb-2004	06112447.8		WO 2004/072051	19-Nov-2010	HK1091831	Granted/Registered
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	India	09-Feb-2004	1845/CHENP/2005		WO 2004/072051	19-Feb-2009	229727	Granted/Registered
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	Japan	09-Feb-2004	2006-502254		WO 2004/072051	10-Feb-2012	4921162	Granted/Registered
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	Republic of Korea	09-Feb-2004	10-2005-7014738		WO 2004/072051	12-Jul-2012	7014738	Granted/Registered
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	Kazakhstan	09-Feb-2004	200501272			28-Apr-2008	009919	Granted/Registered
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	Moldova	09-Feb-2004	200501272			28-Apr-2008	009919	Granted/Registered

Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	Mexico	09-Feb-2004	PA/a/2005/008335	WO 2004/072051	04-Feb-2011	283694	Granted/Registered
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	New Zealand	09-Feb-2004	541479	WO 2004/072051	12-Mar-2009	541479	Granted/Registered
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	Russian Federation	09-Feb-2004	200501272		28-Apr-2008	009919	Granted/Registered
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	Tajikistan	09-Feb-2004	200501272		28-Apr-2008	009919	Granted/Registered
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	Turkmenistan	09-Feb-2004	200501272		28-Apr-2008	009919	Granted/Registered
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	United States of America	09-Feb-2004	10/544443	WO 2004/072051	27-Apr-2010	7705027	Granted/Registered
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	South Africa	09-Feb-2004	2005/06836	WO 2004/072051	25-Oct-2008	2005/06836	Granted/Registered

Part B - Applications

Owners	Country	Application Date	Application No.	Publication No.	Registration Date	Registration No.	Case Status
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	Australia	26-Aug-2004	2004268820	WO 2005/021552	03-Nov-2011	2004268820	Application allowed
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	Brazil	26-Aug-2004	PI0413861-9	WO 2005/021552			Examination report received
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	Canada	26-Aug-2004	2637135	WO 2005/021552			Examination report received
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	Russian Federation	26-Aug-2004	200600509		28-Apr-2008	009920	Application filed

Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	European Patent Office	26-Aug-2004	04768197.8	1675861			Examination report received
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	India	26-Aug-2004	1046/CHENP/2006	WO 2005/021552			Application filed.
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	Norway	26-Aug-2004	2006 1416	WO 2005/021552			Application filed
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	United States of America	26-Aug-2004	12/690983	WO 2005/021552			Examination report received
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	Brazil	09-Feb-2004	PI0407403-3	WO 2004/072051			Application filed
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	European Patent Office	09-Feb-2004	04709273.9	1611112	22-Aug-2012	1611112	EP Granted
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	Albania	09-Feb-2004	04709273.9	1611112	22-Aug-2012	1611112	EP National Phase Entered
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	Austria	09-Feb-2004	04709273.9	1611112	22-Aug-2012	1611112	EP National Phase Entered
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	Belgium	09-Feb-2004	04709273.9	1611112	22-Aug-2012	1611112	EP National Phase Entered
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	Bulgaria	09-Feb-2004	04709273.9	1611112	22-Aug-2012	1611112	EP National Phase Entered
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	Switzerland	09-Feb-2004	04709273.9	1611112	22-Aug-2012	1611112	EP National Phase Entered
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	Cyprus	09-Feb-2004	04709273.9	1611112	22-Aug-2012	1611112	EP National Phase Entered
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	Czech Republic	09-Feb-2004	04709273.9	1611112	22-Aug-2012	1611112	EP National Phase Entered

Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	Denmark	09-Feb-2004	04709273.9	1611112	22-Aug-2012	1611112	EP National Phase Entered
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	Estonia	09-Feb-2004	04709273.9	1611112	22-Aug-2012	1611112	EP National Phase Entered
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	Spain	09-Feb-2004	04709273.9	1611112	22-Aug-2012	1611112	EP National Phase Entered
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	Finland	09-Feb-2004	04709273.9	1611112	22-Aug-2012	1611112	EP National Phase Entered
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	France	09-Feb-2004	04709273.9	1611112	22-Aug-2012	1611112	EP National Phase Entered
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	United Kingdom	09-Feb-2004	04709273.9	1611112	22-Aug-2012	1611112	EP National Phase Entered
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	Greece	09-Feb-2004	04709273.9	1611112	22-Aug-2012	1611112	EP National Phase Entered
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	Hungary	09-Feb-2004	04709273.9	1611112	22-Aug-2012	1611112	EP National Phase Entered
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	Italy	09-Feb-2004	04709273.9	1611112	22-Aug-2012	1611112	EP National Phase Entered
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	Lithuania	09-Feb-2004	04709273.9	1611112	22-Aug-2012	1611112	EP National Phase Entered
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	Luxembourg	09-Feb-2004	04709273.9	1611112	22-Aug-2012	1611112	EP National Phase Entered
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	Latvia	09-Feb-2004	04709273.9	1611112	22-Aug-2012	1611112	EP National Phase Entered
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	Monaco	09-Feb-2004	04709273.9	1611112	22-Aug-2012	1611112	EP National Phase Entered

Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	Macedonia (F.Y.R.O.M)	09-Feb-2004	04709273.9	1611112	22-Aug-2012	1611112	EP National Phase Entered
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	Netherlands	09-Feb-2004	04709273.9	1611112	22-Aug-2012	1611112	EP National Phase Entered
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	Portugal	09-Feb-2004	04709273.9	1611112	22-Aug-2012	1611112	EP National Phase Entered
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	Romania	09-Feb-2004	04709273.9	1611112	22-Aug-2012	1611112	EP National Phase Entered
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	Sweden	09-Feb-2004	04709273.9	1611112	22-Aug-2012	1611112	EP National Phase Entered
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	Slovenia	09-Feb-2004	04709273.9	1611112	22-Aug-2012	1611112	EP National Phase Entered
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	Slovakia	09-Feb-2004	04709273.9	1611112	22-Aug-2012	1611112	EP National Phase Entered
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	Turkey	09-Feb-2004	04709273.9	1611112	22-Aug-2012	1611112	EP National Phase Entered
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	Norway	09-Feb-2004	2005 4195	WO 2004/072051			Examination report received
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	United States of America	09-Feb-2004	12/708686	WO 2004/072051			Examination report received
Vernalis (Cambridge) Ltd;The Institute of Cancer Research;Cancer Research Technology Limited	United States of America	09-Feb-2004	13/625409				Application filed

EXECUTED and DELIVERED
for and on behalf of
VERNALIS (CAMBRIDGE) LIMITED
acting by a director
in the presence of:

la Gascuña

Learn Learn

KEVIN P KISSANE

Witness address:

SOLICITUR

EXECUTED and DELIVERED
for and on behalf of
VERNALIS (R&D) LIMITED
acting by a director
in the presence of:

Director

1 dec. 1 dec.

KEVIN P KISSANE

AE above

de a bove